Johnson & Johnson (JNJ) Offering Possible 34.77% Return Over the Next 14 Calendar Days

Johnson & Johnson's most recent trend suggests a bearish bias. One trading opportunity on Johnson & Johnson is a Bear Call Spread using a strike $141.00 short call and a strike $146.00 long call offers a potential 34.77% return on risk over the next 14 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $141.00 by expiration. The full premium credit of $1.29 would be kept by the premium seller. The risk of $3.71 would be incurred if the stock rose above the $146.00 long call strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Johnson & Johnson is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Johnson & Johnson is bearish.

The RSI indicator is at 27.93 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Johnson & Johnson

AstraZeneca Gets Chile, Peru Nod To Resume COVID-19 Vaccine Trials
Thu, 05 Nov 2020 02:26:06 +0000
AstraZeneca plc (NYSE: AZN) has received the regulatory nod to conduct clinical trials of its COVID-19 vaccine in Chile and Peru, Reuters reported Wednesday.What Happened: Chile's President Sebastian Pinera said that his nation's health regulator had approved the British company's vaccine trial, according to Reuters.According to Pinera, the clinical trial of Johnson & Johnson (NYSE: JNJ) COVID-19 vaccine candidate is already underway and the doses of Sinovac's vaccine arrived in the country on Wednesday.Peru announced that trials of Johnson and Johnson and AstraZeneca vaccines would begin next week, according to Reuters. The country had withdrawn a deal to purchase AstraZeneca's vaccine two weeks ago as the company did not provide data on its vaccine studies. Why It Matters: Pinera also disclosed that Chile had signed up for 7.6 million doses of vaccine through the World Health Organization-led COVAX initiative.The World Bank is supporting COVAX and WHO's efforts and has pledged billion in financing for developing countries to purchase and distribute COVID-19 vaccines, tests, and treatments.The United Kingdom-based AstraZeneca already has deals for the production and supply of its COVID-19 vaccine with multiple Latin American countries.Price Action: AstraZeneca shares closed nearly 6.5% higher at $55.04 on Wednesday and gained 0.11% in the after-hours session.See more from Benzinga * Click here for options trades from Benzinga * B Bitcoin Linked To FBI-Seized Darknet Market Silk Road Is On The Move After 5 Years: Report * Trump Declares Victory Ahead Of Results From Key States(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Republican Hold On Senate Seen As Plus For Drug Companies
Wed, 04 Nov 2020 21:39:53 +0000
While the presidential race is undecided awaiting final results from key states, it appears Republicans could retain control of the Senate, and AbbVie stock and other biotech stocks rose.

Novavax Announces Covid-19 Vaccine Supply Deal With Australia
Wed, 04 Nov 2020 21:29:02 +0000
Novavax announced its latest Covid-19 vaccine deal, with Australia, and confirmed that it's on pace to release final-phase clinical trials data by the first quarter of 2021. NVAX stock rose.

Psychedelic Drug Stock Jumps After State Ballot Legalizes Therapy
Wed, 04 Nov 2020 21:17:21 +0000
Compass Pathways rallied after Oregon legalized psilocybin therapy and Washington, D.C., decriminalized the hallucinogenic substance.

Chilean president says regulators okay AstraZeneca COVID vaccine trial
Wed, 04 Nov 2020 20:42:26 +0000
Chilean President Sebastian Pinera said on Wednesday the country's health regulators had given the go-ahead to a clinical trial of the AstraZeneca PLC COVID-19 vaccine. Pinera said the AstraZeneca trial would follow one by America's Johnson & Johnson that is already underway and another by China's Sinovac, whose first vaccine doses arrived in Chile on Wednesday.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.